349 related articles for article (PubMed ID: 3014000)
1. Human retroviral env and gag polypeptides: serologic assays to measure infection.
Kanner SB; Cheng-Mayer C; Geffin RB; Parks WP; Beltz GA; Arthur LO; Samuel KP; Papas TS
J Immunol; 1986 Jul; 137(2):674-8. PubMed ID: 3014000
[TBL] [Abstract][Full Text] [Related]
2. Retroviruses associated with leukemia and ablative syndromes in animals and in human beings.
Essex M; McLane MF; Kanki P; Allan J; Kitchen L; Lee TH
Cancer Res; 1985 Sep; 45(9 Suppl):4534s-4538s. PubMed ID: 2990682
[TBL] [Abstract][Full Text] [Related]
3. HTLV and immunosuppression.
Essex M; Kanki P; Allan J; Barin F; McLane MF; Lee TH; Kitchen L; Homma T; Malone G; Yokota T
Princess Takamatsu Symp; 1984; 15():309-18. PubMed ID: 6100649
[TBL] [Abstract][Full Text] [Related]
4. Current status and strategies for vaccines against diseases induced by human T-cell lymphotropic retroviruses (HTLV-I, -II, -III).
Fischinger PJ; Robey WG; Koprowski H; Gallo RC; Bolognesi DP
Cancer Res; 1985 Sep; 45(9 Suppl):4694s-4699s. PubMed ID: 2410115
[TBL] [Abstract][Full Text] [Related]
5. Sera from HTLV-III/LAV antibody-positive individuals mediate antibody-dependent cellular cytotoxicity against HTLV-III/LAV-infected T cells.
Rook AH; Lane HC; Folks T; McCoy S; Alter H; Fauci AS
J Immunol; 1987 Feb; 138(4):1064-7. PubMed ID: 3027168
[TBL] [Abstract][Full Text] [Related]
6. New human T-lymphotropic retrovirus related to simian T-lymphotropic virus type III (STLV-IIIAGM).
Kanki PJ; Barin F; M'Boup S; Allan JS; Romet-Lemonne JL; Marlink R; McLane MF; Lee TH; Arbeille B; Denis F
Science; 1986 Apr; 232(4747):238-43. PubMed ID: 3006256
[TBL] [Abstract][Full Text] [Related]
7. Sera from patients with multiple sclerosis react with human cell T lymphotropic virus-I gag proteins but not env proteins--Western blotting analysis.
Ohta M; Ohta K; Mori F; Nishitani H; Saida T
J Immunol; 1986 Dec; 137(11):3440-3. PubMed ID: 3023483
[TBL] [Abstract][Full Text] [Related]
8. Structural and epidemiological features of primate lymphotropic retroviruses.
Hunsmann G; Schneider J; Bayer H; Jurkiewicz E; Yamamoto N
Princess Takamatsu Symp; 1984; 15():109-18. PubMed ID: 6100632
[TBL] [Abstract][Full Text] [Related]
9. Immunological properties of HTLV-III antigens recognized by sera of patients with AIDS and AIDS-related complex and of asymptomatic carriers of HTLV-III infection.
Sarngadharan MG; diMarzo Veronese F; Lee S; Gallo RC
Cancer Res; 1985 Sep; 45(9 Suppl):4574s-4577s. PubMed ID: 2410106
[TBL] [Abstract][Full Text] [Related]
10. Production of oncogene-specific proteins and human T-cell leukemia (lymphotropic) retrovirus (HTLV-I) envelope protein in bacteria and its potential for use in human cancers and seroepidemiological surveys.
Papas TS; Samuel KP; Kan NC; Ascione R; Wong-Staal F; Lautenberger JA
Cancer Res; 1985 Sep; 45(9 Suppl):4568s-4573s. PubMed ID: 2861893
[TBL] [Abstract][Full Text] [Related]
11. [Molecular biology of human T-lymphotropic retroviruses (HTLV)].
Dorner F; Barrett PN; Schmidt BL; Bodemer W
Wien Med Wochenschr; 1986 Apr; 136(7-8):181-8. PubMed ID: 2425498
[TBL] [Abstract][Full Text] [Related]
12. Radioimmunoassay and enzyme-linked immunoassay of antibodies to the core protein (P24) of human T-lymphotropic virus (HTLV III).
Neurath AR; Strick N; Sproul P; Baker L; Rubinstein P; Stevens CE; Taylor P; Gallo RC; Gold JW; Lee YS
J Virol Methods; 1985 May; 11(1):75-86. PubMed ID: 2989312
[TBL] [Abstract][Full Text] [Related]
13. Role of the HTLV-III/LAV envelope in syncytium formation and cytopathicity.
Sodroski J; Goh WC; Rosen C; Campbell K; Haseltine WA
Nature; 1986 Jul 31-Aug 6; 322(6078):470-4. PubMed ID: 3016552
[TBL] [Abstract][Full Text] [Related]
14. Structural and antigenic characterization of the proteins of human T-cell leukemia viruses and their relationships to the gene products of other retroviruses.
Oroszlan S; Copeland TD; Rice NR; Smythers GW; Tsai WP; Yoshinaka Y; Shimotohno K
Princess Takamatsu Symp; 1984; 15():147-57. PubMed ID: 6100635
[TBL] [Abstract][Full Text] [Related]
15. Antigens of human T-lymphotropic virus type III/lymphadenopathy-associated virus.
Essex M; Allan J; Kanki P; McLane MF; Malone G; Kitchen L; Lee TH
Ann Intern Med; 1985 Nov; 103(5):700-3. PubMed ID: 2996402
[TBL] [Abstract][Full Text] [Related]
16. In vitro infection of human monocytes with human T lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV).
Nicholson JK; Cross GD; Callaway CS; McDougal JS
J Immunol; 1986 Jul; 137(1):323-9. PubMed ID: 3011909
[TBL] [Abstract][Full Text] [Related]
17. Virus envelope protein of HTLV-III represents major target antigen for antibodies in AIDS patients.
Barin F; McLane MF; Allan JS; Lee TH; Groopman JE; Essex M
Science; 1985 May; 228(4703):1094-6. PubMed ID: 2986291
[TBL] [Abstract][Full Text] [Related]
18. Delineation of type-specific regions on the envelope glycoproteins of human T cell leukemia viruses.
Chen YM; Zhang XQ; Dahl CE; Samuel KP; Schooley RT; Essex M; Papas TS
J Immunol; 1991 Oct; 147(7):2368-76. PubMed ID: 1717557
[TBL] [Abstract][Full Text] [Related]
19. Absence of human T-lymphotrophic virus type I in patients with systemic lupus erythematosus.
Lipka K; Tebbe B; Finckh U; Rolfs A
Clin Exp Dermatol; 1996 Jan; 21(1):38-42. PubMed ID: 8689767
[TBL] [Abstract][Full Text] [Related]
20. Expression of AIDS virus envelope gene in recombinant vaccinia viruses.
Hu SL; Kosowski SG; Dalrymple JM
Nature; 1986 Apr 10-16; 320(6062):537-40. PubMed ID: 3008002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
